Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS).

Methods

Using data from a longitudinal MS survey, we generated 10-year disease progression paths for an MS cohort. We used first-order annual Markov models to estimate transitional probabilities. Costs associated with losses of employment were obtained from the Bureau of Labor Statistics. Medical costs were estimated using the Centers for Medicare and Medicaid Services reimbursement rates and other sources. Outcomes were measured as gains in quality-adjusted life-years (QALY) and relapse-free years. Monte Carlo simulations, resampling methods, and sensitivity analyses were

SUBMITTER: Noyes K 

PROVIDER: S-EPMC3140799 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature